QualityStocksNewsBreaks – VolitionRx Ltd. (NYSE American: VNRX) Highlights Clinical and Commercial Progress Across Diagnostics Portfolio
VolitionRx Limited (NYSE American: VNRX) provided a corporate update highlighting recent clinical and commercial progress, including submission of a feline lymphoma manuscript tied to a potential $5 million milestone payment, alongside continued momentum in licensing discussions with more than a dozen global diagnostic and liquid biopsy companies. The company also highlighted advancements across its diagnostic pipeline, including validation progress for its Capture-Seq cancer detection platform, expansion of its sepsis-focused Nu.Q NETs program and ongoing efforts to secure reimbursement in France for its lung cancer assay ahead of anticipated routine clinical use. To view the full press release, visit https://ibn.fm/nX9FK About Volition Volition is a multi-national company focused on…